BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 26648164)

  • 21. Trastuzumab enhances the anti-tumor effects of the histone deacetylase inhibitor sodium butyrate on a HER2-overexpressing breast cancer cell line.
    Chen W; Wei F; Xu J; Wang Y; Chen L; Wang J; Guan X
    Int J Mol Med; 2011 Dec; 28(6):985-91. PubMed ID: 21887460
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vitro activity of the mTOR inhibitor everolimus, in a large panel of breast cancer cell lines and analysis for predictors of response.
    Hurvitz SA; Kalous O; Conklin D; Desai AJ; Dering J; Anderson L; O'Brien NA; Kolarova T; Finn RS; Linnartz R; Chen D; Slamon DJ
    Breast Cancer Res Treat; 2015 Feb; 149(3):669-80. PubMed ID: 25663547
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Metformin and the mTOR inhibitor everolimus (RAD001) sensitize breast cancer cells to the cytotoxic effect of chemotherapeutic drugs in vitro.
    Liu H; Scholz C; Zang C; Schefe JH; Habbel P; Regierer AC; Schulz CO; Possinger K; Eucker J
    Anticancer Res; 2012 May; 32(5):1627-37. PubMed ID: 22593441
    [TBL] [Abstract][Full Text] [Related]  

  • 24. S-adenosylhomocysteine hydrolase inhibition by 3-deazaneplanocin A analogues induces anti-cancer effects in breast cancer cell lines and synergy with both histone deacetylase and HER2 inhibition.
    Hayden A; Johnson PW; Packham G; Crabb SJ
    Breast Cancer Res Treat; 2011 May; 127(1):109-19. PubMed ID: 20556507
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MiRNA‑542‑3p downregulation promotes trastuzumab resistance in breast cancer cells via AKT activation.
    Ma T; Yang L; Zhang J
    Oncol Rep; 2015 Mar; 33(3):1215-20. PubMed ID: 25586125
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nexrutine inhibits survival and induces G1 cell cycle arrest, which is associated with apoptosis or autophagy depending on the breast cancer cell line.
    Yan G; Lanza-Jacoby S; Wang C
    Nutr Cancer; 2014; 66(3):506-16. PubMed ID: 24206214
    [TBL] [Abstract][Full Text] [Related]  

  • 27. ErbB-2 inhibition activates Notch-1 and sensitizes breast cancer cells to a gamma-secretase inhibitor.
    Osipo C; Patel P; Rizzo P; Clementz AG; Hao L; Golde TE; Miele L
    Oncogene; 2008 Aug; 27(37):5019-32. PubMed ID: 18469855
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Furanodienone induces cell cycle arrest and apoptosis by suppressing EGFR/HER2 signaling in HER2-overexpressing human breast cancer cells.
    Li YW; Zhu GY; Shen XL; Chu JH; Yu ZL; Fong WF
    Cancer Chemother Pharmacol; 2011 Nov; 68(5):1315-23. PubMed ID: 21461888
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Characterizations of irofulven cytotoxicity in combination with cisplatin and oxaliplatin in human colon, breast, and ovarian cancer cells.
    Serova M; Calvo F; Lokiec F; Koeppel F; Poindessous V; Larsen AK; Laar ES; Waters SJ; Cvitkovic E; Raymond E
    Cancer Chemother Pharmacol; 2006 Apr; 57(4):491-9. PubMed ID: 16075278
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Benzopyran derivative CDRI-85/287 induces G2-M arrest in estrogen receptor-positive breast cancer cells via modulation of estrogen receptors α- and β-mediated signaling, in parallel to EGFR signaling and suppresses the growth of tumor xenograft.
    Saxena R; Fatima I; Chandra V; Blesson CS; Kharkwal G; Hussain MK; Hajela K; Roy BG; Dwivedi A
    Steroids; 2013 Nov; 78(11):1071-86. PubMed ID: 23891847
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Calcitriol and its analogues enhance the antiproliferative activity of gefitinib in breast cancer cells.
    Segovia-Mendoza M; Díaz L; González-González ME; Martínez-Reza I; García-Quiroz J; Prado-Garcia H; Ibarra-Sánchez MJ; Esparza-López J; Larrea F; García-Becerra R
    J Steroid Biochem Mol Biol; 2015 Apr; 148():122-31. PubMed ID: 25510900
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Enhanced sensitization to taxol-induced apoptosis by herceptin pretreatment in ErbB2-overexpressing breast cancer cells.
    Lee S; Yang W; Lan KH; Sellappan S; Klos K; Hortobagyi G; Hung MC; Yu D
    Cancer Res; 2002 Oct; 62(20):5703-10. PubMed ID: 12384528
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Stroma cells: a novel target of herceptin activity.
    Corsini C; Mancuso P; Paul S; Burlini A; Martinelli G; Pruneri G; Bertolini F
    Clin Cancer Res; 2003 May; 9(5):1820-5. PubMed ID: 12738740
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fatty acid synthase inhibition by amentoflavone suppresses HER2/neu (erbB2) oncogene in SKBR3 human breast cancer cells.
    Lee JS; Sul JY; Park JB; Lee MS; Cha EY; Song IS; Kim JR; Chang ES
    Phytother Res; 2013 May; 27(5):713-20. PubMed ID: 22767439
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 20-Cyclopropyl-cholecalciferol vitamin D3 analogs: a unique class of potent inhibitors of proliferation of human prostate, breast and myeloid leukemia cell lines.
    Koike M; Koshizuka K; Kawabata H; Yang R; Taub HE; Said J; Uskokovic M; Tsuruoka N; Koeffler HP
    Anticancer Res; 1999; 19(3A):1689-97. PubMed ID: 10470102
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Acridine as an Anti-Tumour Agent: A Critical Review.
    Varakumar P; Rajagopal K; Aparna B; Raman K; Byran G; Gonçalves Lima CM; Rashid S; Nafady MH; Emran TB; Wybraniec S
    Molecules; 2022 Dec; 28(1):. PubMed ID: 36615391
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Coenzyme Q0 induces apoptosis and modulates the cell cycle in estrogen receptor negative breast cancer cells.
    Somers-Edgar TJ; Rosengren RJ
    Anticancer Drugs; 2009 Jan; 20(1):33-40. PubMed ID: 18830129
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Si-Wu-Tang and its constituents promote mammary duct cell proliferation by up-regulation of HER-2 signaling.
    Chang CJ; Chiu JH; Tseng LM; Chang CH; Chien TM; Chen CC; Wu CW; Lui WY
    Menopause; 2006; 13(6):967-76. PubMed ID: 17075435
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Apogossypolone induces autophagy and apoptosis in breast cancer MCF-7 cells in vitro and in vivo.
    Niu X; Li S; Wei F; Huang J; Wu G; Xu L; Xu D; Wang S
    Breast Cancer; 2014 Mar; 21(2):223-30. PubMed ID: 22711315
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Additive effects of trastuzumab and genistein on human breast cancer cells.
    Lattrich C; Lubig J; Springwald A; Goerse R; Ortmann O; Treeck O
    Anticancer Drugs; 2011 Mar; 22(3):253-61. PubMed ID: 21160418
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.